Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Study shows TC chemotherapy superior to AC in disease-free survival among breast cancer patients
January 12th, 2006
The final analysis of an AC/TC adjuvant chemotherapy trial showed that TC (Docetaxel/Cyclophosphamide, 4 cycles) produced a superior disease-free survival compared to four cycles of standard AC (Doxorubicin/Cyclophosphamide) in 1,016 women at 5 years of observation. "At 5 years, the disease-free survival rate was significantly superior for TC compared to AC," said Dr. Stephen Jones, medical director of U.S. Oncology Research and director of breast cancer research at the Texas Oncology - Sammons Cancer Center in Dallas. "Overall survival differences between treatments were not yet statistically significant, but there is a strong trend in favor of TC." ...
Source: Women's Health Weekly (2006-01-12)
|
